An independent peptide reference — no sellers, every claim sourced

Decorin

Also known as DCN, PG-S2, bone proteoglycan II, PG40

An endogenous proteoglycan, not a peptide, studied as an anti-fibrotic TGF-beta trap - almost entirely in animals.

preclinical Recovery & tissue endogenous peptide

At a glance

Category
Recovery & tissue
Status
endogenous peptide
Made from
recombinant Where decorin protein exists at all it is recombinant human decorin made in cell culture; it is a glycosylated proteoglycan, not a synthesisable peptide.
Route
Not administered to humans. Animal work has used recombinant protein by local injection, AAV-mediated gene delivery, skeletal muscle transgene expression, topical eye drops and decorin-loaded hydrogels.
Half-life
No human pharmacokinetics have been published. As a large glycosylated protein it would not be orally bioavailable, and systemic clearance of recombinant decorin has not been characterised in humans.
Molecular weight
Core protein roughly 40 kDa (a 359-residue preproprotein, processed to a mature core of about 330 residues). The mature secreted proteoglycan carries a single chondroitin or dermatan sulfate glycosaminoglycan chain and runs at roughly 90-140 kDa depending on tissue and glycosylation. Gene DCN, chromosome 12q21.33 9.

Decorin is a naturally occurring human extracellular matrix protein, not a synthetic compound. It is not an approved drug anywhere and there is no recognised therapeutic product containing it. It is included in this reference because it appears in peptide vendor listings and in discussions of scar and fibrosis management, but it is a glycosylated small leucine-rich proteoglycan with a core protein of roughly 40 kDa, encoded by DCN on chromosome 12q21.33 9 - orders of magnitude larger than the short peptides it is listed alongside, and with entirely different pharmaceutical requirements.

Doping status: Not listed by WADA

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

A correctly folded and glycosylated recombinant proteoglycan is a demanding manufacturing target, so vials sold as 'decorin' on the peptide market cannot be assumed to contain it.

This is a short entry. There is little or no published research on this compound, so there is correspondingly little to report. Empty dosing or reconstitution sections mean no credible figures exist — not that they were left out.

Mechanism of action

Decorin is a small leucine-rich proteoglycan (SLRP) secreted by fibroblasts into the extracellular matrix. Its established structural role is in collagen fibrillogenesis: it binds along collagen fibrils and constrains their lateral growth, which is why loss-of-function mutations in DCN cause congenital stromal corneal dystrophy, and why decorin-null mice have abnormally coarse, irregular collagen fibres and fragile skin.

The therapeutic interest rests on a second role. Decorin binds and sequesters TGF-beta, the central driver of fibrosis, forming a complex that prevents receptor engagement and thereby dampens downstream Smad2/3 and ERK signalling. This makes it a natural endogenous brake on the fibrotic response, and the logic of supplying more of it in fibrotic disease is straightforward. Decorin additionally binds EGFR, IGF-1R and Met, where it acts as a partial agonist that ultimately downregulates the receptor - which is the basis of a separate literature on decorin as a tumour suppressor.

The gap between that mechanism and a usable therapy is the whole story. Decorin is not a drug candidate in any conventional sense: it is a large, heavily glycosylated matrix protein that cannot be given orally, does not distribute usefully after systemic administration, and would need to reach and persist in a specific tissue compartment to do anything. Every serious preclinical approach has therefore been a delivery problem - gene therapy, local implants or sustained-release biomaterials - rather than an injection of the protein. The idea that a decorin vial could be reconstituted and injected subcutaneously for anti-scarring effect has no basis in the literature.

What the research shows

The anti-fibrotic mechanism is well characterised at the molecular and cellular level and reproduced by multiple independent groups - this is not a fringe hypothesis. But it has never been tested as a therapy in humans. No clinical trial of decorin as an intervention has been published, and the entire translational literature consists of animal models and cell culture.

Research in humans

No published human trials of decorin as a therapeutic. Searches of the clinical literature return only observational and mechanistic studies in which decorin is measured as a biomarker or endpoint - for example circulating decorin in response to exercise training, or matrix protein panels in cardiomyopathy and dietary intervention trials - not studies in which decorin was administered. Human data on DCN come from genetics (congenital stromal corneal dystrophy) and from expression studies showing decorin is downregulated in hypertrophic scars and in scarless fetal wound healing.

Animal and lab research

The preclinical base is reasonably broad. Recombinant human decorin reduces proliferation, TGF-beta1 production and collagen synthesis in cultured hypertrophic scar fibroblasts, and inhibits both basal and TGF-beta1-driven contraction of collagen lattices. Co-overexpression of decorin markedly reduces the lung fibrosis produced by TGF-beta overexpression in rodents, with decorin and biglycan behaving differently in that model. Targeted AAV5 decorin gene therapy significantly reduced corneal haze in rabbit models of corneal fibrosis, along with alpha-smooth-muscle actin, F-actin and fibronectin, and appeared non-immunogenic and non-toxic to the cornea 6. Decorin expressed from skeletal muscle prevented fibrotic kidney disease in rats. Sustained decorin release to the ocular surface produced largely scarless corneal regeneration.

Caveats. Nothing here has been tested in a person. All the encouraging results depend on a delivery route - viral vector, muscle transgene, hydrogel, sustained-release ocular device - which is exactly the part that is hardest to translate and which carries its own risks that the fibrosis models do not assess. Decorin's growth-factor receptor effects cut both ways: the same TGF-beta and receptor tyrosine kinase modulation that is desirable in fibrosis has consequences for wound healing, immune signalling and tumour biology that have not been characterised for exogenous administration. There is no toxicology programme, no immunogenicity assessment for repeated dosing, and no dose-finding of any kind. Material sold as 'decorin' on the grey peptide market is of unverifiable identity - correctly folded, correctly glycosylated recombinant human proteoglycan is a demanding manufacturing target, and there is no reason to assume such products contain it.

What it is used for

  • Preclinical research target in organ fibrosis - lung 4, liver 7, kidney, heart - as a TGF-beta trap
  • Preclinical research in corneal scarring, the most advanced application, via AAV gene delivery 6 and sustained-release formulations 8. Note that the AAV5 rabbit study measured corneal haze, alpha-smooth-muscle actin, F-actin, fibronectin and ocular toxicity - it did not assess neovascularisation
  • Preclinical research in hypertrophic scar and keloid biology 235
  • Studied as a tumour suppressor via EGFR, Met and IGF-1R downregulation 1 - a separate literature from the fibrosis work
  • Marketed on the grey market for scar reduction and anti-fibrotic use; no human evidence supports this and the delivery premise is not credible

Dosing

  • There is no human dose. No dose-finding study, no maximum tolerated dose and no pharmacokinetics exist in any species relevant to human administration.
  • Animal doses cannot be translated because they are inseparable from their delivery vehicle: an AAV vector titre or a hydrogel loading is not convertible into a milligram injection.
  • Any dosing protocol circulating for injectable decorin is invented. Leaving this field empty is the accurate answer.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Safety

Side effects

  • Unknown in humans - no one has been given it, so there is no side effect profile. Absence of reported effects here reflects absence of exposure, not safety
  • Mechanistically anticipated concerns rather than observed ones: impaired wound healing and reduced tensile strength of healing tissue from suppressing TGF-beta, which is required for normal repair 1; immunogenicity against a recombinant protein on repeated administration; and unpredictable effects in tissues where TGF-beta signalling is tumour-suppressive rather than fibrogenic 1
  • For gene therapy approaches specifically, the risk profile is that of the vector, not of decorin

Do not use if

  • There is no established human use, so the honest position is that it should not be self-administered at all
  • Active malignancy - decorin's interactions with EGFR, Met and IGF-1R and with TGF-beta signalling have context-dependent effects on tumour biology that are not predictable in an individual 1
  • Active wound healing or recent surgery - suppressing TGF-beta is the intended effect and is directly at odds with normal repair 15
  • Pregnancy, breastfeeding, children and adolescents - no data of any kind

Interactions

Not systematically studied. Mechanistically, additive or opposing effects would be expected with anything acting on the TGF-beta axis (pirfenidone, nintedanib, TGF-beta-directed antibodies) and with EGFR- or Met-directed oncology agents, but none of this has been tested.

Sources